Episode 38

In this episode, Daphne, Josh, Bruce and Dawn are joined by guest Sam Fazeli (Bloomberg) to discuss this week’s biotech news and trends, including priorities in biotech (patients, investments and incentives), hybrid work models, and the new CEO appointments at Seagen and Biogen. In oncology news, the GSK Blenrep failure in multiple myeloma trial and perspective on progression-free survival versus overall survival in oncology and what really matters. From a financial angle, the hosts discuss single product companies, stock-based compensation, Clovis’ bankruptcy risk, EQRx’s pivot in their pricing model, Merrimack Pharma shares jumping after a successful trial for their pancreatic cancer drug and BioNTech’s increased full-year sales projection. Plus, regulatory news from the week including Verve’s clinical hold and ADC Therapeutics’ accelerated approval rejection. Community of experts and insiders joining Biotech Hangout (formerly known as Biotech Clubhouse) include Daphne Zohar, Josh Schimmer, Bruce Booth, Tim Opler, Chris Garabedian, Michal Preminger, Dawn Bell, Rob Perez, Otello Stampacchia and more.